Atosiban Impurity D is a structurally related byproduct formed during atosiban synthesis, differing subtly in side-chain or ring connectivity. Researchers analyze its chromatographic resolution and spectral signature. The peptide aids in verifying impurity limits and method selectivity. Applications include quality control, peptide-process mapping, and degradation-pathway elucidation.
CAT No: Z10-101-222
Synonyms/Alias:N4-((2R)-1-((2S)-2-((5-amino-1-((2-amino-2-oxoethyl)amino)-1-oxopentan-2-yl)carbamoyl)pyrrolidin-1-yl)-3-mercapto-1-oxopropan-2-yl)-N2-((R)-3-(4-ethoxyphenyl)-2-(3-mercaptopropanamido)propanoyl)-L-isoleucyl-L-threonyl-L-asparagine;
Atosiban impurity D is a structurally related compound that emerges as a byproduct during the synthesis and degradation processes of Atosiban, a well-known oxytocin receptor antagonist. Characterized by its distinct chemical structure, Atosiban impurity D plays a pivotal role in pharmaceutical research and development, particularly in the context of quality control and analytical method validation. Its presence provides crucial insights into the stability, degradation pathways, and synthetic efficiency of peptide-based therapeutics. As a reference standard, Atosiban impurity D is highly valued for its ability to help researchers and manufacturers ensure the integrity and safety of the final pharmaceutical product by identifying and quantifying trace-level impurities. The compound's unique profile also makes it indispensable for advancing analytical chemistry techniques within the pharmaceutical industry.
Pharmaceutical Analysis: Atosiban impurity D is extensively employed as a reference compound in the development and validation of analytical methods, such as high-performance liquid chromatography (HPLC) and mass spectrometry. By serving as a benchmark for impurity profiling, it enables laboratories to accurately detect, identify, and quantify impurities in Atosiban drug substances and formulations. This process is essential for maintaining the consistency and reliability of pharmaceutical products throughout their shelf life. The availability of Atosiban impurity D as a standard ensures that analytical methods are robust, sensitive, and specific, ultimately supporting rigorous quality assurance protocols in pharmaceutical manufacturing.
Peptide Synthesis Research: In peptide chemistry, Atosiban impurity D provides valuable information about the synthetic pathways and potential side reactions that may occur during the production of complex peptide drugs. Researchers utilize this impurity to optimize synthetic routes, minimize byproduct formation, and enhance the overall yield and purity of the target molecule. By studying the formation mechanisms of Atosiban impurity D, chemists can refine reaction conditions, select appropriate protecting groups, and implement purification strategies that reduce impurity levels, contributing to the development of more efficient and cost-effective manufacturing processes.
Degradation Pathway Elucidation: Atosiban impurity D is instrumental in elucidating the degradation pathways of peptide therapeutics under various stress conditions, such as heat, light, moisture, and pH fluctuations. Stability studies that track the generation and transformation of this impurity enable scientists to understand the factors influencing drug degradation and to design formulations with improved stability profiles. The insights gained from these studies inform packaging decisions, storage recommendations, and shelf-life assessments, ensuring that pharmaceutical products remain effective and safe throughout their intended use period.
Bioanalytical Method Development: In the realm of bioanalytical chemistry, Atosiban impurity D is utilized to develop and validate sensitive assays for the detection and quantification of Atosiban and its related substances in biological matrices. These assays are critical for pharmacokinetic and metabolic studies, allowing researchers to monitor drug exposure, distribution, and elimination in preclinical and research settings. By incorporating Atosiban impurity D as a calibration or quality control standard, bioanalytical laboratories can ensure the accuracy and reproducibility of their data, facilitating meaningful interpretation of experimental results.
Impurity Profiling in Regulatory Submissions: For pharmaceutical companies preparing regulatory submissions, comprehensive impurity profiling is a fundamental requirement. Atosiban impurity D serves as a key reference material in the identification and quantification of related substances, supporting the compilation of detailed impurity profiles for investigational and marketed products. Its inclusion in regulatory documentation demonstrates a thorough understanding of the product's chemical composition and manufacturing process, thereby streamlining the approval process and reinforcing the commitment to product quality and patient safety. Through its diverse applications in analytical, synthetic, and regulatory domains, Atosiban impurity D stands as an essential tool for advancing peptide drug research and ensuring the highest standards of pharmaceutical development.
2. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists
3. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More